Seres Therapeutics Q2 EPS $0.36 Misses $0.55 Estimate, Sales $126.47M Beat $125.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
Seres Therapeutics reported Q2 earnings of $0.36 per share, missing the analyst consensus estimate of $0.55 by 34.55%. However, the company's quarterly sales of $126.47 million beat the estimate of $125.50 million by 0.77%. This represents a 151.43% increase in earnings and a 10.3K% increase in sales compared to the same period last year.
August 08, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Seres Therapeutics' Q2 earnings per share missed estimates by 34.55%, but sales exceeded expectations by 0.77%. This could lead to mixed market reactions.
While the earnings miss could negatively impact the stock, the sales beat and significant year-over-year growth could offset this and lead to a neutral or positive market reaction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100